Detalles de la búsqueda
1.
Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1/2 trial and expanded access.
Lancet
; 399(10322): 372-383, 2022 01 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-35065785
2.
Panitumumab use in metastatic colorectal cancer and patterns of RAS testing: results from a Europe-wide physician survey and medical records review.
BMC Cancer
; 17(1): 798, 2017 Nov 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-29183279
3.
Risk of acute liver injury associated with use of antibiotics. Comparative cohort and nested case-control studies using two primary care databases in Europe.
Pharmacoepidemiol Drug Saf
; 25 Suppl 1: 29-38, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-27038354
4.
Literature review of visual representation of the results of benefit-risk assessments of medicinal products.
Pharmacoepidemiol Drug Saf
; 25(3): 238-50, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26521865
5.
Recommendations for benefit-risk assessment methodologies and visual representations.
Pharmacoepidemiol Drug Saf
; 25(3): 251-62, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26800458
6.
Benefit-risk assessment in a post-market setting: a case study integrating real-life experience into benefit-risk methodology.
Pharmacoepidemiol Drug Saf
; 23(9): 974-83, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-25043919
7.
Malignancy in Giant Cell Tumor of Bone: A Review of the Literature.
Technol Cancer Res Treat
; 18: 1533033819840000, 2019 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30935298
8.
Real-World Use of Talimogene Laherparepvec in German Patients with Stage IIIB to IVM1a Melanoma: A Retrospective Chart Review and Physician Survey.
Adv Ther
; 36(1): 101-117, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30536143
9.
Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma.
J Immunother Cancer
; 7(1): 145, 2019 06 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31171039
10.
Randomized study of dual versus single ritonavir-enhanced protease inhibitors for protease inhibitor-experienced patients with HIV.
HIV Clin Trials
; 9(2): 91-102, 2008.
Artículo
en Inglés
| MEDLINE | ID: mdl-18474494
11.
A review of methods for comparing treatments evaluated in studies that form disconnected networks of evidence.
Res Synth Methods
; 9(2): 148-162, 2018 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-29073336
12.
Practical clinical guide on the use of talimogene laherparepvec monotherapy in patients with unresectable melanoma in Europe.
Eur J Dermatol
; 28(6): 736-749, 2018 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30698145
13.
Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB-IVM1c melanoma.
Melanoma Res
; 28(1): 44-51, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29176501
14.
Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial.
Onco Targets Ther
; 9: 7081-7093, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27895500
15.
Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results.
AIDS
; 19(2): 145-52, 2005 Jan 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-15668539
16.
Panitumumab Use in Metastatic Colorectal Cancer and Patterns of KRAS Testing: Results from a Europe-Wide Physician Survey and Medical Records Review.
PLoS One
; 10(10): e0140717, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26491871
17.
Evaluation of cutpoints for phenotypic hypersusceptibility to efavirenz.
AIDS
; 17(16): 2395-6, 2003 Nov 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-14571193
18.
A randomized trial of treatment interruption before optimized antiretroviral therapy for persons with drug-resistant HIV: 48-week virologic results of ACTG A5086.
J Infect Dis
; 194(9): 1309-18, 2006 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-17041858
19.
DEET mosquito repellent sold through social marketing provides personal protection against malaria in an area of all-night mosquito biting and partial coverage of insecticide-treated nets: a case-control study of effectiveness.
Trop Med Int Health
; 9(3): 343-50, 2004 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-14996363
20.
DEET mosquito repellent provides personal protection against malaria: a household randomized trial in an Afghan refugee camp in Pakistan.
Trop Med Int Health
; 9(3): 335-42, 2004 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-14996362
Resultados
1 -
20
de 20
1
Próxima >
>>